1859 is a platform company that combines artificial intelligence with empirical pico-scale screening data to discover new small-molecule medicines. Its core “design, build, test, learn” engine uses next-generation DNA-encoded libraries, bead-encoded libraries, and proprietary pico-scale screening to explore billions of molecular starting points and rapidly synthesize and test target-tailored compounds. The platform couples large-scale functional screening with AI predictions, allowing the company to validate hits, retrain models, and iterate quickly on chemistries. 1859 partners with pharmaceutical, biotech, and academic collaborators and has a base of 16 partners for advancing preclinical discovery programs. The company says the funding will be used to develop new capabilities, scale its platform, and advance preclinical programs. 1859 was incubated at JLABS in San Diego, employs 53 people, and was founded in 2019.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2022